No Scientific Evidence to Support Drug Safety Recommendations
During the past several years there has been a perceived drug safety ...A recent editorial published in Health Economics finds no scientific...The current drug controversy is largely due to the withdrawal of Vio...The IOM report does not document for example whether the reduction...The editorial points to a study that the social benefit from reducin...
During the past several years, there has been a perceived drug safety crisis in the United States.//
A recent editorial published in Health Economics finds no scientific evidence to back up the IOM’s recommendations released recently and little evidence of a drug safety crisis.
The current drug controversy is largely due to the withdrawal of Vioxx from the market, but the decrease in drug approval times thanks to the Prescription Drug User Fee Acts (PDUFA), and undue influence from the pharmaceutical industry that these acts may have invited have also played a role. Yet the scientific basis that too many unsafe drugs enter the market is lacking.
The IOM report does not document, for example, whether the reductions in approval times for bringing drugs to the market negatively affects the well-being of consumers.
The editorial points to a study that the social benefit from reducing drug approval times from 1979 to 2002 —a sum estimated at $16 to $32 billion dollars—substantially outweighed any decrease in safety.
Although a lengthier approval process might reduce the number of drug withdrawals, this doesn’t necessarily mean that too many drugs are withdrawn.
Removing a few drugs from the market may be a necessary price to pay for bringing a larger number of medications more quickly to the public.
The report recommends a two-year ban on advertising drugs directly to consumers because it may lead to increased exposure to unsafe drugs, but it would also mean that fewer consumers would benefit from these medications.
Also, it is not clear if restricting this advertising would limit consumption since it represents only a 15% share of total advertising expenditures.
The authors agree with the report’s recommendation that extensive testing should be done after drugs are on the market. “The science of approval is far more elaborate than the science of withdrawal, many times done under gr '"/>
(Date:11/27/2009)...Newswire-FirstCall/ -- The Gymboree Corporation (N...OO, will present at the NASDAQ OMX 23rd Investor P...n London, England, on Wednesday, December 2, 2009,...dcast of The Gymboree Corporation,s presentation o...m, click on "Our Company" at the bottom of the pag...
(Date:11/27/2009)...ldings has announced that it has become a national...argest nonprofit organizations dedicated to arthri... Delray Beach, FL (Vocus) Novemb...O), a company specializing in the marketing and re... has announced today that is has become a national...
(Date:11/27/2009)...th™ announced today that Spectrum Health (Gr...nterprise orthopedic templating solution and its T... (PRWEB) November 27, 2009 -- Voyant He...Grand Rapids, Michigan) has licensed its TraumaCad... TraumaCad Extend workflow solution, to allow its ...
(Date:11/26/2009)...wire/ -- With cold and flu season upon us, it,s mo... control the spread of infections and avoid illnes... ourselves healthy, but to avoid transmitting illn...IC (certified in infection-control), nursing direc...at Hospital for Special Surgery (HSS) in Manhattan...
(Date:11/26/2009)...an lead to strains or worse , , THURSDAY... wrong with stuffing your turkey full to bursting,...your suitcase as you pack for holiday trips. , ...S. hospital emergency rooms, doctors, offices, cli...ted injuries, such as muscle strains, pulls and te...
...SEATTLE, July 30 Preliminary results from Millima...emium rate increases continue,to exceed the govern...an,premium increases in recent years. The 2009 est...rend toward lower,increases since peaking at 16.1%...
...TORONTO, July 30 Dyadem today announced that it h...y-based builder of,production equipment for the ph...dem,s FMEA-Med software to help its customers mini...ecialized machines for,pharmaceutical companies. A...
...SALT LAKE CITY, July 30 ARUP Laboratories, a nati...innovative laboratory research,and development, an...istance-learning arena, have entered into a person...rtner to,provide enhanced opportunities for ARUP c...
...BURLINGAME, Calif., July 30 Extend Health(R) toda...fficer at Revolution,Health, LLC, and Paul Kirinci...d analysis at Netflix, Inc., are joining Extend He... on,August 18 and joins as senior vice president a...
...Study in Tijuana points to need for cross-border p...Y, July 30 (HealthDay News) -- The odds of HIV inf...sers who were deported to Tijuana from the United ...l AIDS Conference in Mexico City, suggest further ...
..., Adiponectin, a protein produced by fat cells, m...diovascular health for older Americans according t...rnal of Clinical Endocrinology & Metabolism (JCEM...has been associated with lower occurrence of diabe...
(Date:11/25/2009)...T BRUNSWICK, N.J., Nov. 25 Swissra...rect digital Radiography ( ddR ) systems, announce...a private Swiss Investor with a long term view tow... acquisition included all assets and intellectual ...r 25 years of success and growth Swissray is now p...
(Date:11/25/2009)...NEW YORK, Nov. 25 Reportlinker.com...ailable in its catalogue: ,, Pain Management ...om/p0164220/Pain-Management---Global-Trends.html ...ergence of pain management clinics, and the advent...in the pain management market. Healthcare reforms ...
(Date:11/25/2009)...N VIEW, Calif., Nov. 25 ChemoCen...ical data from the Company,s PROTECT-1 (the Prospe...s disease Trial) of Traficet-EN(TM) (CCX282-B) in ...emonstrated clinical efficacy with a favorable saf...ted evidence of clinical efficacy in the reduction...
...Begins to Demonstrate Strategy to Expand NHL Marke...ng Preclinical Development Program -, BRITISH COL.... (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF;, h... commercializing the next,generation of monoclonal...,Linking (DXL(TM)), announced today the results of...
...zerland, September 16 Mymetics,Corporation (OTCBB... to,announce their preliminary SHIV challenge resu...h the Company,s mucosal HIV-AIDS vaccine designed,...nificantly exceed the,Industry standard of 60% to ...vaccine as well as of Mymetics, expectation which ...
... The ENDOPATH EZ45 Endoscopic Linear Cutter has ap...sive surgical procedures for transection, resectio...with staple line or tissue buttressing materials s...aded seven times for a total of eight firings. Dif...
ETS-Flex Endoscopic Articulating Linear Cutter
ENDOPATH ETS Compact-Flex45 Articulating Linear Cutters
... The Auto Suture ENDO CLIP MultApplier reusable cl...MultApplier single-use loading unit, each of which...rall length of the shaft of the instrument is appr...igned for introduction and use through an appropri...